Tumor necrosis factor microsatellite markers TNFa5b5 and TNFa6b5 influence adverse reactions to parenteral gold in Caucasians

Journal of Rheumatology

Volumn 26, Issue 11, 1999, Pages 2303-2309

  Evans, Toni I ^a   Small, Ralph E ^c   Redford, Thomas W ^b   Han, Jinfeng ^c   Moxley, George ^c  

^a CAROLINAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Hunter Holmes McGuire Vet Aff M ^*

Author keywords

Adverse effects; Antirheumatic agents; Gold; HLA antigens; Tumor necrosis factor

Indexed keywords

GOLD; HLA ANTIGEN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; GENOTYPE; HAPLOTYPE; HEMATURIA; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HLA-DR ANTIGENS; HUMANS; INFUSIONS, PARENTERAL; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; ORGANOGOLD COMPOUNDS; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032704943     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Wise CM, Bruzzese J, Roberts WN. More aggressive drug treatment of rheumatoid arthritis in a university-based practice. J Clin Rheumatol 1995;1:227-31.
2. Adachi JD, Bensen WG, Kassam Y, et al. Gold induced thrombocytopenia: 12 cases and a review of the literature. Semin Arthritis Rheum 1987;16:287-93.
3. Cobyln JS, Weinblatt M, Holdsworth D, Glass D. Gold-induced thrombocytopenia. Ann Intern Med 1981;95:178-81.
4. Davies DJ, Dowling J, Xipell JM. Gold nephropathy. Pathology 1977;9:281-8.
5. Skrifvars BV, Tornroth TS, Tallqvist GN. Gold-induced immune complex nephritis in seronegative rheumatoid arthritis. Ann Rheum Dis 1977;36:549-56.
6. Barger BO, Acton RT, Koopman WJ, Alarcon GS. DR antigens and gold toxicity in white rheumatoid arthritis patients. Arthritis Rheum 1984;27:601-5.
7. Bensen WG, Moore N, Tugwell P, D'Souza M, Singal DP. HLA antigens and toxic reactions to sodium aurothiomalate in patients with rheumatoid arthritis. J Rheumatol 1984;11:358-61.
8. Rantapaa Dahlqvist S, Strom H, Bjelle A, Moller E. HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. Clin Rheumatol 1985;4:55-61.
9. LeGrand L, Lathrop GM, Marcelli-Barge A, et al. HLA-DR genotype risks in seropositive rheumatoid arthritis. Am J Hum Genel 1984;36:690-9.
10. Singal DP, Green D, Reid B, Gladman DD, Buchanan WW. HLA-D region genes and rheumatoid arthritis (RA): importance of DR and DQ genes in conferring susceptibility to RA. Ann Rheum Dis 1992;51:23-8.
11. Bardin T, LeGrand L, Naveau B, et al. HLA antigens and seronegative rheumatoid arthritis. Ann Rheum Dis 1985;44:50-3.
12. Rodriguez-Perez M, Gonzalez-Dominguez J, Mataran L, Garcia-Perez S, Salvatierra D. Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate. J Rheumatol 1994;21:41-3.
13. Speerstra F, van Riel PL, Reekers P, van de Putte LB, Vandenbroucke JP. The influence of HLA phenotypes on the response to parenteral gold in rheumatoid arthritis. Tissue Antigens 1986;28:1-7.
14. Panayi GS, Wooley P, Batchelor JR. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. BMJ 1978;2:1326-8.
15. Singal DP, Reid B, Green D, D'Souza M, Bensen WG, Buchanan WW. Polymorphism of major histocompatibility complex extended haplotypes bearing HLA-DR3 in patients with rheumatoid arthritis with gold induced thrombocytopenia or proteinuria. Ann Rheum Dis 1990;49:582-6.
16. Wooley PH, Griffin J, Panayi GS, Batchelor JR, Welsh KI, Gibson MB. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980;303:300-2.
17. Perrier P, Raffoux C, Thomas P, et al. HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine in patients with rheumatoid arthritis. Ann Rheum Dis 1985;44:621-4.
18. Van Gestel A, Koopman R, Wijnands M, van de Putte L, van Riel P. Mucocutaneous reactions to gold: a prospective study of 74 patients with rheumatoid arthritis. J Rheumatol 1994;21:1814-9.
19. Pickl WF, Fischer GF, Faé I, Kolarz G, Scherak O. HLA-DR1-positive patients suffering from rheumatoid arthritis are at high risk for developing mucocutaneous side effects upon gold therapy. Hum Immunol 1993;38:127-31.
20. Clarkson RW, Sanders PA, Grennan DM. Complement C4 null alleles as a marker of gold or D-penicillamine toxicity in the treatment of rheumatoid arthritis. Br J Rheumatol 1992;31:53-4.
21. Karr RW, Rodey GE, Lee T, Schwartz BD. Association of HLA-DRw4 with rheumatoid arthritis in black and white patients. Arthritis Rheum 1980;23:1241-5.
22. Dequeker J, Wanghe PV, Verdickt W. A systematic survey of HLA-A, B, C and D antigens and drug toxicity in rheumatoid arthritis. J Rheumatol 1984;11:282-6.
23. Majoos FL, Klemp P, Meyers OL, Briggs B. Gold therapy in rheumatoid arthritis. SA Med 1981;59:971-4.
24. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
25. Meyer JM, Han J, Singh R, Moxley G. Sex influences on the penetrance of HLA shared-epitope genotypes for rheumatoid arthritis. Am J Hum Genet 1996;58:371-83.
26. Moxley G. Immunoglobulin kappa genotype confers risk of rheumatoid arthritis among HLA-DR4 negative individuals. Arthritis Rheum 1989;32:1365-70.
27. Moxley G. Variable-constant segment genotype of immunoglobulin kappa is associated with increased risk for rheumatoid arthritis. Arthritis Rheum 1992;35:19-25.
28. Bidwell JL, Jarrold EA. HLA-DR allogenotyping using exon-specific cDNA probes and application of rapid minigel methods. Mol Immunol 1986;23:1111-6.
29. Bidwell J. DNA-RFLP analysis and genotyping of HLA-DR and DQ antigens. Immunol Today 1988;9:18-23.
30. Scharf SJ, Griffith RL. Erlich HA. Rapid typing of DNA sequence polymorphism at the HLA-DRB1 locus using the polymerase chain reaction and nonradioactive oligonucleotide probes. Human Immunol 1991;30:190-201.
31. Kimura A, Sasazuki T. Eleventh International Histocompatibility Workshop reference protocol for the HLA DNA-typing technique. In: Tsuji K, Aizawa M, Sasazuki T, editors. HLA 1991. Oxford: Oxford University Press; 1992:397-419.
32. Inoko H, Ota M. PCR-RFLP. In: Hui KM, Bidwell JL, editors. Handbook of HLA typing techniques. Boca Raton:CRC press; 1993:9-70.
33. Jawaheer D, Ollier WER, Thomson W. Multiplex ARMS-RFLP: a simple and rapid method for HLA-DR4 subtyping. Eur J Immunogenet 1993;20:175-87.
34. Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turetskaya RL. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 1993;16:180-6.
35. Monos DS, Kamoun M, Udalova IA, et al. Genetic polymorphism of the human tumor necrosis factor region in insulin-dependent diabetes mellitus - linkage disequilibrium of TNFab microsatellite alleles with HLA haplotypes. Hum Immunol 1995;44:70-9.
36. Brinkman BMN, Huizinga TWJ, Kurban SS, et al. Tumor necrosis factor a gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol 1997;36:516-21.
37. Terwilliger JD, Ott J. Linkage disequilibrium between alleles at marker loci. In: Terwilliger JD, Ott J, editors. Handbook for human genetic linkage. Baltimore: Johns Hopkins University Press; 1994:188-98.
38. MacGregor A, Ollier W, Thomson W, Jawaheer D, Silman A. HLA-DRB 1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol 1995;22:1032-6.
39. Hajeer A, John S, Ollier WE, Silman AJ, et al. Tumor necrosis factor microsatellite haplotypes are different in male and female patients with RA. J Rheumatol 1997;24:217-9.
40. Ford PM. HLA antigens and drug toxicity in rheumatoid arthritis. J Rheumatol 1984;11:259-61.
41. Hall CL. Drugs, systemic diseases, and the kidney. Adv Exp Med Biol 1989;252:247-56.
42. Alarcon GS, Barger BO, Acton RT, Koopman WJ. HLA antigens and gold toxicity in American blacks with rheumatoid arthritis. Rheumatol Int 1986;6:13-7.
43. Ott J. Analysis of human genetic linkage. 2nd ed. Baltimore: Johns Hopkins University Press; 1991.
44. Wilson AG, De Vries N, Pociot F, Di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLAA1, B8, and DR3 alleles. J Exp Med 1993;177:557-60.
45. Degli-Esposti MA, Leaver AL, Christiansen FT, Witt CS, Abraham LJ. Dawkins RL. Ancestral haplotypes: conserved population MHC haplotypes. Hum Immunol 1992;34:242-52.